AmnioFix vs AmnioAMP: Dehydrated Membrane Comparison

AmnioFix vs AmnioAMP compared for wound care: MiMedx dHACM vs AmnioAMP-MP on tissue form, processing, 361 HCT/P status, evidence, and HCPCS coding.

Published 2026-10-01 | Clinical education for wound care physicians, podiatrists, nurses, and wound-center medical directors
By Josh Fathi, Founder, NextGen Biologics
Reviewed by the NextGen Biologics clinical editorial team against cited sources
This content is informational and not medical advice; it is not a substitute for professional diagnosis or treatment.

AmnioFix vs AmnioAMP: Direct Answer

AmnioFix (MiMedx) and AmnioAMP-MP (NextGen Biologics) are both dehydrated, shelf-stable human amniotic membrane products regulated as Section 361 HCT/Ps for homologous use in wound care — but they are not interchangeable. AmnioFix is a dehydrated human amnion/chorion membrane (dHACM) with the largest published wound-care trial program in the category; AmnioAMP-MP is a decellularized dehydrated human amniotic membrane (DDHAM) positioned for wound and tissue-repair applications. Clinically, the honest answer is that there is no head-to-head randomized trial between them, so product choice should follow the wound type, the evidence behind each product's indications, workflow fit, and the product-specific HCPCS coding pathway — not brand preference.

| Factor | AmnioFix (MiMedx) | AmnioAMP-MP (NextGen Biologics) | Clinical implication | |---|---|---|---| | Tissue form | Dehydrated human amnion/chorion membrane (dHACM), micronized/sheet configurations | Decellularized dehydrated human amniotic membrane (DDHAM) | Same broad dehydrated class; confirm the specific configuration against the IFU | | Growth-factor / HC-HA retention | dHACM processing retains native growth factors and HC-HA; retention claims are product-specific per manufacturer processing | Decellularization + dehydration per IFU; request product-specific retention data | Retention claims must trace to published or manufacturer data, not class assumptions | | Processing | Proprietary PURION-style dehydration process (MiMedx) | Dehydration with decellularization per AmnioAMP IFU | Different validated processes; do not extrapolate between them | | Regulatory status | Section 361 HCT/P (minimally manipulated, homologous use) | Section 361 HCT/P (minimally manipulated, homologous use) | Neither is a 510(k) device or 351 biologic; keep claims within homologous use | | Published wound-care evidence | Level I DFU RCT (PMID 25424146), confirmatory DFU RCT (PMID 30136445), VLU RCT (PMID 29024419), category review (PMID 32580594) | Product-specific IFU indications; class-level dHACM evidence applies cautiously (PMID 36104736) | Strongest branded evidence sits with AmnioFix trials; AmnioAMP-MP selection should cite the specific indication | | HCPCS coding | Product-specific code — verify against the current CMS HCPCS file for the specific AmnioFix configuration billed | AmnioAMP-MP maps to Q4250 per CMS HCPCS application | Q-codes are product-specific and not interchangeable; verify before billing |

For the adjacent comparisons in this cluster, see AmnioAMP vs EpiFix and AmnioAMP vs Rampart DL Matrix; for processing-method differences, see the dehydrated vs cryopreserved decision guide.

What Each Product Is

AmnioFix is a dehydrated human amnion/chorion membrane (dHACM) product line from MiMedx Group, Inc. used as a biologic covering or scaffold in chronic and complex wounds. The wound-care AmnioFix evidence base is the deepest in the dehydrated-membrane category, anchored by randomized trials in diabetic foot ulcers and venous leg ulcers. A category review (Massey et al., PMID 32580594) summarizes the up-to-date role of dHACM — including AmnioFix — in wound healing. AmnioAMP-MP is a decellularized dehydrated human amniotic membrane (DDHAM) distributed by NextGen Biologics through Stratus BioSystems channels, mapped to HCPCS Q4250. Its indications per IFU cover wound-care applications; where branded randomized trials are absent, clinicians should treat class-level dHACM evidence (PMID 36104736) as hypothesis-generating rather than product-proving.

Both are regulated under Section 361 of the Public Health Service Act as HCT/Ps — human cell or tissue-based products that are exempt from device/biologic marketing authorization when minimally manipulated and intended for homologous use. That status constrains claims on both sides: neither product's marketing, nor this comparison, can promise treatment outcomes beyond homologous-use indications.

The Evidence Base, Claim by Claim

No PubMed-indexed head-to-head randomized trial compares AmnioFix to AmnioAMP-MP directly. What exists is a strong branded evidence program on the MiMedx side and class-level evidence that AmnioAMP-MP clinicians can cite with appropriate caveats.

Diabetic foot ulcers. The landmark dHACM comparative-effectiveness trial (Zelen et al., PMID 25424146) randomized 60 patients across three arms — dHACM, a bioengineered skin substitute, and standard of care. The dHACM arm closed 85% of DFUs by week 4 and 95% by week 6 versus 35%/45% for the substitute and 30%/35% for standard care (adjusted P ≤ 0.003); median time to healing was 13 days versus 49 days. A 100-patient follow-up (Zelen et al., PMID 26695998) reported 97% 12-week closure with dHACM versus 73% and 51% for the comparators (adjusted P = 0.00019), a healing hazard ratio of 5.66, and a median graft cost per healed wound of $1,517 versus $8,918. The confirmatory multicenter RCT (Tettelbach et al., PMID 30136445) randomized 110 patients at 14 wound clinics: 70% ITT closure at 12 weeks with dHACM versus 50% with standard care (P = 0.0338). A 2024 RCT (Cazzell et al., PMID 38973638) again favored dehydrated amnion/chorion membrane over standard of care in DFUs, and a comparative RCT against a high-purity collagen skin substitute (Narayan et al., PMID 39649230) provides the only recent branded-product comparison in this space. Venous leg ulcers. Serena et al. (PMID 25224019) randomized VLU patients to dHACM plus multilayer compression versus compression alone; Bianchi et al. (PMID 29024419) confirmed efficacy in a multicenter RCT. Serena et al. (PMID 26551645) additionally showed that the 4-week wound-area response predicts 24-week closure — a practical continuation signal for any dehydrated-membrane program, AmnioFix or AmnioAMP-MP alike. Class-level synthesis. The 2022 systematic review and meta-analysis of human amniotic membrane products for DFUs (Mohammed et al., PMID 36104736) concluded these products improve healing versus standard care. Cost-effectiveness analyses in DFUs (Driver et al., PMID 35148642; Nherera et al., PMID 38524772) and VLUs (Tettelbach et al., PMID 38457298) consistently find dHACM cost-effective under episode-cost framing, and Carter et al. (PMID 38832861) evaluated cost-per-cm² justification for cellular/tissue products in DFUs. In refractory VLUs, a recent cohort (Nagasaki et al., PMID 41802539) reported 82.7% complete healing in 52 treatment-refractory cases. Important caveat. Sabol et al. (PMID 36032519) showed that amnion/amnion-chorion allograft studies report outcomes inconsistently across ITT and per-protocol analyses — Tettelbach's own confirmatory trial shifts materially between the two (PMID 30864259). Product-to-product comparisons that ignore this are unreliable. The defensible clinical position: the AmnioFix trial program is the category benchmark, and AmnioAMP-MP selection should be justified by the specific wound type, the IFU indication, and the class-level evidence with the no-head-to-head limitation disclosed.

Where the Injectable Question Fits

Searchers landing on "amniofix injections" are usually asking whether dehydrated amniotic membrane can be delivered beyond a sheet graft — into tunnels, undermined areas, or as a micronized application. Both product families have addressed this workflow question, but the regulatory frame matters: within 361 HCT/P homologous-use rules, application configuration must match the manufacturer's validated indications and IFU. Wound clinicians should verify the current IFU for the specific configuration being applied and document indication, prior standard-of-care failure, and vascular status in the same note — payer denials most often trace to those three elements being split across documents. Medicare debridement-interval data around dHACM application (PMID 36240797) also show outcomes are sensitive to wound-bed preparation, not just product choice.

Where NextGen Biologics fits: if your wound-care program is evaluating dehydrated amniotic membrane products — whether the AmnioAMP-MP line or a comparison against AmnioFix for a specific indication — NextGen Biologics can supply product-specific IFUs, HCPCS mapping documentation, and evaluation samples for your value analysis committee. Request samples to run the comparison on your own wound mix.

Reimbursement Context

HCPCS Q-codes are product-specific. AmnioAMP-MP maps to Q4250; Rampart DL Matrix maps to Q4347; the two are not interchangeable, and the AmnioFix configuration billed must be verified against the current CMS HCPCS file rather than assumed from class membership. Under the CMS skin-substitute payment restructuring, outpatient amniotic membrane reimbursement moved toward a standardized flat-rate framework (approximately $127/cm² per the CY 2026 PFS/OPPS rules), shifting the economic question from per-unit price to total episode cost — applications used, healing trajectory, and complications. A higher per-unit price can be rational if it reduces application count; a lower price is not a bargain if healing slows. Verify current rates with your local MAC.

Practical Selection Framework

Before applying either product:

- Confirm wound etiology is established and consistent with the specific product's IFU. - Document failed standard of care: debridement, infection control, offloading/compression, moisture balance. - Assess and document vascular status for lower-extremity wounds. - Confirm wound-bed preparation is complete: clean base, hemostasis, biofilm controlled. - Match the product's published evidence to the wound type — DFU evidence is strongest; VLU evidence is narrower. - Verify the product-specific HCPCS mapping and payer criteria before the first application. - Disclose the absence of head-to-head branded data in VAC dossiers and patient conversations.

Frequently Asked Questions

Are AmnioFix and AmnioAMP the same product?

No. AmnioFix is MiMedx's dHACM product line; AmnioAMP-MP is NextGen Biologics' DDHAM product mapped to Q4250. Both are Section 361 HCT/Ps, but processing, evidence bases, and HCPCS mappings differ per product.

Is there a head-to-head trial of AmnioFix vs AmnioAMP?

No PubMed-indexed head-to-head randomized trial exists. The strongest branded evidence belongs to the AmnioFix dHACM trial program (PMID 25424146; PMID 30136445; PMID 29024419); AmnioAMP-MP selection should cite IFU indications plus class-level evidence (PMID 36104736) with the limitation disclosed.

Can dehydrated amniotic membrane be used as an injectable?

Application configuration must match the manufacturer's validated IFU within homologous-use rules. Clinicians searching "amniofix injections" should verify the current MiMedx IFU for the configuration in question and document indication and prior standard-of-care failure accordingly.

Which has better evidence for diabetic foot ulcers?

The dHACM randomized program behind AmnioFix (85–95% closure by 4–6 weeks in the Zelen trial, PMID 25424146) is the category benchmark. The 2022 meta-analysis (PMID 36104736) supports the broader amniotic-membrane class for DFUs.

Are the HCPCS codes interchangeable between the two products?

No. Q-codes are product-specific. AmnioAMP-MP maps to Q4250; verify the AmnioFix configuration's code against the current CMS HCPCS file before billing — never substitute codes across products.

Related Resources

- Amniotic Membrane Science Guide: Placental Allografts

References

1. Zelen CM, et al. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. Int Wound J. 2015. PMID: 25424146. 2. Zelen CM, et al. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study. Int Wound J. 2016. PMID: 26695998. 3. Tettelbach W, et al. A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of chronic diabetic foot ulcers. Wound Repair Regen. 2019. PMID: 30136445. 4. SerenaGroup, et al. A multicenter, randomized, controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane in lower extremity ulcers. Int Wound J. 2014. PMID: 25224019. 5. SerenaGroup, et al. Dehydrated human amnion/chorion membrane treatment of venous leg ulcers: correlation between 4-week and 24-week outcomes. J Wound Care. 2015. PMID: 26551645. 6. Bianchi C, et al. A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane in venous leg ulcers. Int Wound J. 2018. PMID: 29024419. 7. DiDomenico LA, et al. Use of an aseptically processed, dehydrated human amnion and chorion membrane improves likelihood and rate of healing in chronic diabetic foot ulcers. Int Wound J. 2018. PMID: 30019528. 8. Mohammed H, et al. Human amniotic membrane products for patients with diabetic foot ulcers — do they help? A systematic review and meta-analysis. Int Wound J. 2022. PMID: 36104736. 9. Massey CJ, et al. Up-to-date role of the dehydrated human amnion/chorion membrane (AMNIOFIX) for wound healing. 2020. PMID: 32580594. 10. Driver VR, et al. Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcers. Int Wound J. 2022. PMID: 35148642. 11. Nherera LM, et al. Cost effectiveness analysis for commonly used human cell and tissue products in the management of diabetic foot ulcers. J Tissue Viability. 2024. PMID: 38524772. 12. Tettelbach W, et al. Dehydrated human amnion chorion membrane to treat venous leg ulcers: a cost-effectiveness analysis. J Wound Care. 2024. PMID: 38457298. 13. Carter MJ, et al. Counting the cost of cellular and/or tissue-based products in diabetic foot ulcers. Wounds. 2025. PMID: 38832861. 14. Sabol KM, et al. Standardized reporting of amnion and amnion/chorion allograft data for wound care. J Wound Care. 2022. PMID: 36032519. 15. Walters J, et al. Outcomes for Medicare debridement intervals receiving dehydrated human amnion/chorion membrane. 2022. PMID: 36240797. 16. Tettelbach W, et al. Variations in study outcomes relative to intention-to-treat and per-protocol data analysis techniques in the evaluation of dHACM. 2019. PMID: 30864259. 17. Cazzell S, et al. Dehydrated amnion chorion membrane versus standard of care for diabetic foot ulcers: a randomised controlled trial. 2024. PMID: 38973638. 18. Narayan DP, et al. A randomized controlled clinical trial comparing high-purity type-I collagen-based skin substitute with dehydrated human amnion/chorion membrane in DFU. 2024. PMID: 39649230. 19. Nagasaki Y, et al. Clinical outcomes and prognostic determinants of dehydrated human amnion/chorion membrane for refractory venous leg ulcers. 2026. PMID: 41802539.